Chemistry:Arformoterol

From HandWiki
Revision as of 03:34, 6 February 2024 by JStaso (talk | contribs) (simplify)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Arformoterol
Arformoterol.svg
Arformoterol ball-and-stick model.png
Clinical data
Trade namesBrovana
Other namesArformoterol tartrate (USAN US)
AHFS/Drugs.comMonograph
MedlinePlusa602023
License data
Routes of
administration
Inhalation
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Protein binding52–65%
Elimination half-life26 hours
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC19H24N2O4
Molar mass344.411 g·mol−1
 ☒N☑Y (what is this?)  (verify)

Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]

It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as a generic medication.[3]

Medical uses

Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]

References

  1. 1.0 1.1 1.2 1.3 1.4 "Brovana- arformoterol tartrate solution". 13 May 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839. 
  2. "Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease". Expert Opinion on Drug Safety 14 (3): 463–72. March 2015. doi:10.1517/14740338.2015.998196. PMID 25563342. 
  3. "Competitive Generic Therapy Approvals". 29 June 2023. https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals. 

External links